文献速递流行病学与生物统计临床试验与 GCP

相对风险在临床研究中的效用争议:呼吁改变实践

Controversy and Debate: Questionable utility of the relative risk in clinical research: Paper 1: A call for change to practice.
PubMed 文献 · J Clin Epidemiol · 2020-11-07

论文通过数学推导并分析Cochrane 140,620项试验,指出相对风险(RR)受结局基线 prevalence 影响而向无效值偏移,不能单独反映效应大小;优势比(OR)仅衡量效应强度且与 prevalence 无关,建议临床试验与Meta分析改用OR,并以OR重算绝对风险。

要点

  • RR随结局基线 prevalence 升高而向无效值偏移,与效应强度无关。
  • OR仅衡量效应强度,与结局 prevalence 无关,且不低估RR。
  • 建议临床试验与Meta分析停用RR作为主要效应量,改用OR。

核心结论

  • RR因依赖基线 prevalence 而无法直接解释效应大小,应停止在临床试验与Meta分析中作为主要报告指标。
  • 建议以OR替代RR,并用由OR重算的干预后风险进行绝对解释(如NNT)。

研究设计与样本

  • 数学推导确定RR是否单独衡量效应大小及其与结局 prevalence 的关系。
  • 对Cochrane 140,620项试验的后续分析验证推导结果。

主要发现

  • RR是两个后验概率之比,二者均依赖结局基线 prevalence,故RR变化不单反映效应大小。
  • RR随结局 prevalence 增加而向无效值偏移,且与干预-结局关联强度无关。
  • OR仅衡量效应强度,与结局 prevalence 无关,也不像通常认为的那样高估RR。

关键数值与推荐

  • 后续分析纳入140,620项Cochrane试验验证推导。
  • 推荐(1)终止RR在临床试验与Meta分析中的主要使用;(2)以OR替代RR;(3)按OR重算预期基线风险下的绝对风险用于解释(如NNT)。

临床怎么用

  • 临床试验与Meta分析报告效应量时优先采用OR而非RR。
  • 解释干预效果时,按OR重算预期基线风险下的绝对风险(如NNT)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: In clinical trials, the relative risk or risk ratio (RR) is a mainstay of reporting of the effect magnitude for an intervention. The RR is the ratio of the probability of an outcome in an intervention group to its probability in a control group. Thus, the RR provides a measure of change in the likelihood of an event linked to a given intervention. This measure has been widely used because it is today considered a measure with "portability" across varying outcome prevalence, especially when the outcome is rare. It turns out, however, that there is a much more important problem with this ratio, and this paper aims to demonstrate this problem. METHODS: We used mathematical derivation to determine if the RR is a measure of effect magnitude alone (i.e., a larger absolute value always indicating a stronger effect) or not. We also used the same derivation to determine its relationship to the prevalence of an outcome. We confirm the derivation results with a follow-up analysis of 140,620 trials scraped from the Cochrane. RESULTS: We demonstrate that the RR varies for reasons other than the magnitude of the effect because it is a ratio of two posterior probabilities, both of which are dependent on baseline prevalence of an outcome. In addition, we demonstrate that the RR shifts toward its null value with increasing outcome prevalence. The shift toward the null happens regardless of the strength of the association between intervention and outcome. The odds ratio (OR), the other commonly used ratio, measures solely the effect magnitude and has no relationship to the prevalence of an outcome in a study nor does it overestimate the RR as is commonly thought. CONCLUSIONS: The results demonstrate the need to (1) end the primary use of the RR in clinical trials and meta-analyses as its direct interpretation is not meaningful, (2) replace the RR by the OR, and (3) only use the postintervention risk recalculated from the OR for any expected level of baseline risk in absolute terms for purposes of interpretation such as the number needed to treat. These results will have far-reaching implications such as reducing misleading results from clinical trials and meta-analyses and ushering in a new era in the reporting of such trials or meta-analyses in practice.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Doi SA, Furuya-Kanamori L, Xu C, et al. Controversy and Debate: Questionable utility of the relative risk in clinical research: Paper 1: A call for change to practice. J Clin Epidemiol. 2020. PMID: 33171273. doi:10.1016/j.jclinepi.2020.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。